Further Developments towards a Minimal Potent Derivative of Human Relaxin-2

• Published in: International journal of molecular sciences 2023-08, Vol.24 (16), p.12670
• Main Authors: Handley, Thomas N. G., Praveen, Praveen, Tailhades, Julien, Wu, Hongkang, Bathgate, Ross A. D., Hossain, Mohammed Akhter
• Format: Article
• Language: English
• Subjects: 7BP; Amino acids; B7-33; B9-31; Chronic obstructive pulmonary disease; Communication; Competition; fibrosis; Heart rate; human relaxin-2; Hydrocarbons; Mutation; Peptides; Pharmaceutical industry; RXFP1; Wound healing
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241612670

Human relaxin-2 (H2 relaxin) is a peptide hormone with potent vasodilatory and anti-fibrotic effects, which is of interest for the treatment of heart failure and fibrosis. H2 relaxin binds to the Relaxin Family Peptide Receptor 1 (RXFP1). Native H2 relaxin is a two-chain, three-disulfide-bond-containing peptide, which is unstable in human serum and difficult to synthesize efficiently. In 2016, our group developed B7-33, a single-chain peptide derived from the B-chain of H2 relaxin. B7-33 demonstrated poor affinity and potency in HEK cells overexpressing RXFP1; however, it displayed equivalent potency to H2 relaxin in fibroblasts natively expressing RXFP1, where it also demonstrated the anti-fibrotic effects of the native hormone. B7-33 reversed organ fibrosis in numerous pre-clinical animal studies. Here, we detail our efforts towards a minimal H2 relaxin scaffold and attempts to improve scaffold activity through Aib substitution and hydrocarbon stapling to re-create the peptide helicity present in the native H2 relaxin.